logo
Share SHARE
FONT-SIZE Plus   Neg

Genmab Announces First Phase III Trial Of Daratumumab - Quick Facts

Denmark-based biotechnology company Genmab A/S (GNMSF.PK) said its partner, Janssen Biotech, Inc. would begin a Phase III study of daratumumab in relapsed or refractory multiple myeloma. The trial would compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone.

Genmab's Chief Executive stated: "The daratumumab development program is progressing very well. We are extremely pleased to be able to announce that this study evaluating daratumumab in combination with a core multiple myeloma treatment regime will initiate patient recruitment in the coming months."

The Phase III trial would comprise nearly 500 patients with relapsed or refractory multiple myeloma. Patients would be randomized to receive either daratumumab combined with lenalidomide and dexamethasone, or lenalidomide and dexamethasone alone. The company said the study's primary endpoint is progression free survival.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Snapchat created a furor after dropping the Best Friends feature which allowed users to see who their contacts had been sharing snaps with the most. But the ephemeral messaging service provider soon vowed to reinstate the feature to assuage users who said Best Friends helped them ensure fidelity. Chinese e-commerce giant Alibaba reported a 28 percent drop in third-quarter profit, hurt by stock-based compensation expense and other costs. Meanwhile revenues surged 40 percent, driven by growth in China commerce retail business, though not at the rate analysts expected, even as its active user base ballooned. Alibaba shares dropped 9% on the NYSE. McDonald's has announced its Chief Executive Office Don Thompson will be "retiring" at the age of 51, after two tumultuous years on the job. It will instead be up to Steve Easterbrook, 48, McDonald's chief brand officer, to reverse a downturn in fortunes for the iconic hamburger chain. His challenges...
comments powered by Disqus
Follow RTT